- Reuters•last month
India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising competition in its lucrative U.S. dermatology business, its U.S. chief said. The world's fifth-largest maker of generic drugs was the first among its Indian peers to enter the roughly $5 billion U.S. dermatology space by acquiring a controlling stake in Israel's Taro Pharmaceutical Industries Ltd in 2010.
- Bloomberg•last month
Indian drugmakers are embarking on a research spending spree to master more complex therapies and their billionaire founders look willing to absorb the costs.
|52wk Range||1,280.00 - 2,129.00|
|Day's Range||1,678.25 - 1,704.90|
|Avg Vol (3m)||1,203,775|
As of 5:59 AM EDT. Market closed.